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Abstract: The detection of prion protein in widely used urine-derived fertility 
drugs has raised the possibility that prions from urine donors with 
(asymptomatic) prion disease could be present in these drugs. A high level of 
uncertainty exists regarding this issue. An international expert panel provided 
judgments related to prion disease transmission through fertility drug use in a 
structured expert elicitation. The elicitation gauged expert judgements about the 
uncertainty surrounding potential prion disease risks associated with 
 urine-derived fertility drugs and emphasised the scientific ambiguity 
surrounding disease transmission risk factors associated with urine-derived 
fertility drugs. Group aggregated responses indicate that the theoretical risk of 
prion disease transmission with urine-derived fertility drugs was judged to be 
very low. The experts judged recombinant fertility drugs produced with bovine 
serum to possess 10-fold lower risk compared to urine-derived fertility drugs. 
Fertility drugs made without fetal bovine serum were judged to present a risk 
approximately 1,200 times lower compared to urine-derived counterparts. This 
elicitation indicates recombinant fertility drugs carry relatively less risk than 
urine-derived fertility drugs. However, the associated uncertainties are 
significant and pro-active surveillance of possible new routes of transmission of 
human prion disease warrants consideration of new scientific data as it 
becomes available. 
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1 Introduction 
Creutzfeldt-Jakob disease (CJD) is a human neurodegenerative disorder that is currently 
incurable and invariably fatal. CJD can be classified into four forms: 
1 iatrogenic 
2 familial 
3 sporadic 
4 variant (Sikorska et al., 2012). 
Evidence suggests variant CJD (vCJD) may occur due to transmission of prions from 
cattle to human through the consumption of contaminated meat products derived from 
affected cattle in the food chain (Brown, 2001; Bruce, 2000; Chen et al., 2013). 
Over the last two decades the scientific understanding of the etiology of prion 
diseases has advanced considerably yielding a better understanding of how these diseases 
are transmitted both within and between species through contact with infectious prions 
(Sikorska et al., 2012; Hueston, 2013; Gough and Maddison, 2010). Prion diseases are 
postulated to be produced by misfolding of a benign, ubiquitously expressed cellular 
prion protein (PrPC) into a distinct pathological conformation termed scrapie prion 
protein (PrPSc), which is considered the infectious and amplifiable disease agent 
(Prusiner, 1998). 
Prion proteins were found to be excreted from infected animals through multiple 
routes including skin, feces, urine, saliva, blood, milk, placenta and nasal secretions 
(Gough and Maddison, 2010). Potential routes of transmission for developing human 
prion disease include surgical procedures, blood transfusion, injection of contaminated 
cadaveric human growth hormone and consumption of contaminated meat products 
(Chen et al., 2013; Hamaguchi et al., 2009; Puopolo et al., 2011; Croes et al., 2002). 
Van Dorsselaer et al. (2011) reported the detection of normal prion protein in  
urine-derived fertility drugs using advanced proteomics techniques. Urine-derived drugs 
are comprised of human menopausal gonadotropins (hMG) or menotropins extracted 
from female urine that contains follicle stimulating hormone (FSH), luteinising hormone 
(LH) (e.g., pergonal, menogon) and low levels of human chorionic gonadotropin (hCG). 
FSH and LH are found in high amounts in urine of post-menopausal women. hMG is 
derived as a purified extract from the urine of post-menopausal women and is a powerful 
and effective drug that stimulates the ovaries to produce multiple follicles. Injections of 
hMG are given repeatedly over several days in the first half of the cycle and induce 
ovulation in approximately 75%–85% of patients attempting to conceive as a way to 
overcome infertility problems (Van De Weijer et al., 2003; Wolfenson et al., 2005). 
The detection of prion protein in urine-derived fertility drugs raises the possibility of 
a new route of transmission of human prion disease, which could conceivably occur if 
infectious prions were present in urine samples donated by an asymptomatic CJD or 
vCJD case (Reichl et al., 2002). This route of transmission remains a theoretical 
possibility as there are no apparent documented cases of prion disease reported following 
the use of urine-derived gonadotropins. To evaluate the likelihood of transmission of  
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human prion disease through the use of urine-derived fertility drugs in the absence of data 
on transmission rates, a group of international experts on prion disease was consulted to 
obtain their views on this issue. This consultation was undertaken in the form of a 
structured expert elicitation, a technique that has been successfully previously used to 
evaluate uncertainty associated with a wide range of issues (Cooke and Goossens, 2008; 
Aspinall, 2010) including prion disease risk uncertainties (Tyshenko et al., 2011; 2012). 
Expert elicitations of this type may provide useful information regarding potential 
risks, for which conventional assessment is not possible due to the lack of current 
scientific data. The findings may be used to make informed decisions regarding risk 
management options for mitigating prion disease risks related to treatment with  
urine-derived fertility drugs. The expert elicitation process has the advantage that it 
provides a synthesis of science-based support for policy responses allowing regulators to 
conduct risk assessments under a precautionary paradigm to address emerging threats at 
an early stage, despite the absence of definitive scientific evidence. 
The overall goal of the expert elicitation described in this paper was to assess the 
likelihood that cases of human prion disease may occur through the therapeutic use of 
urine-derived fertility drugs contaminated with infectious prions. 
2 Methods 
2.1 Expert elicitation 
The core protocol for the expert elicitation involves two sets of questions. The experts 
were first asked to answer a series of seed questions related to prion disease for which 
values are, in principle, knowable, based on existing data. However, the seed items were 
chosen by an independent facilitator, in such a way that while the experts are not 
expected to know precise values they are expected to ‘capture’ these values quantitatively 
by providing judicious estimates of medians and related 90% credible interval quantiles. 
The experts were then asked to answer, again with median estimate and credible 
range, a series of target questions related to the objectives of the elicitation; these values 
are subject to greater uncertainty because of the lack of data relating to the specific 
issues. The seed questions were used to calibrate expert uncertainty judgement in the 
field of prion disease. Individual responses to the target questions were weighted by the 
expert’s performance on the seed questions, leading to an aggregated group judgement 
for each of the target questions, along with an assigned quantitative indicator of 
uncertainty surrounding that response (both weighted and unweighted analysis of the 
responses from the experts to the target questions are typically presented in elicitations of 
this type). 
The authors developed 26 target questions for the present elicitation exercise. The 
questions were grouped into four categories: 
1 The prevalence of asymptomatic prion disease in the general population (questions 
1–16). 
2 The presence of infectious prions in the urine pools used in the manufacture of 
fertility drugs (questions 17–18). 
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3 Transmission of prion disease through the use of urine-derived fertility drugs 
(questions 19–22). 
4 The relative risk of transmitting prion disease through the use of urine-derived and 
recombinant fertility drugs (questions 23–26). 
The expert elicitation on uncertainties associated with risks and benefits of treatment with 
urine-derived and recombinant fertility drugs was held on October 8–9, 2011, at the 
International Prevention Research Institute (IPRI) in Lyon, France. More than 20 people 
attended the elicitation workshop, including seven experts who participated actively in 
the structured elicitation exercise for quantifying uncertainties relating to the transmission 
of prion diseases via administration of fertility drugs to women. One of the original eight 
experts did not complete all the seed questions, so the responses of that expert to the 
target questions could not be used in the overall elicitation analysis. The persons 
participating in the elicitation were selected for their internationally recognised expertise 
with respect to prion disease risk issues and for the absence or declaration of conflict of 
interest in providing their judgements regarding the issues. 
Each expert was asked to provide responses in the form of two quantiles defining the 
5th and 95th percentile values for their judged uncertainty distribution for each question 
(i.e., 90% credible interval). They also provided a 50th percentile quantity, to represent 
their judgment of the appropriate central value for the question. The collective response 
of the seven experts was calculated in two ways: 
1 unweighted, treating all experts’ judgements as equally valid 
2 performance weighted, taking into account the performance of the experts on the 
seed questions. 
The results of the expert elicitation were analysed using the Classical Model for 
combining expert opinions via the EXCALIBUR software package, which is described in 
detail in previous publications (Cooke and Goosens, 2008; Cooke, 1991). The 
EXCALIBUR software package can be freely downloaded at: 
http://www.expertsinuncertainty.net/Publications/Excalibur/tabid/4386/Default.aspx. 
2.2 Strategy ranking elicitation 
In a second exercise, experts were asked to rank different strategies for managing risks of 
development of prion disease from taking fertility drugs, by suggesting what weights 
could be distributed across the strategies with the ultimate the purpose of ranking 
alternative risk management approaches. These weights were then used as a basis for 
comparing the relative effectiveness of each strategy. In this exercise, eight risk 
management strategies were identified by the authors before the elicitation workshop; 
and two additional strategies were added to the list following discussion by the expert 
group during the workshop. The final list of 10 potential strategies for managing the risk 
of developing prion disease from treatment with urine-derived fertility drugs were: 
1 donor selection/sourcing from countries without CJD 
2 donor selection/sourcing based on time spent in the UK 
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3 donor selection/sourcing based on blood transfusion, neurosurgery, or treatment with 
growth hormone 
4 implementing a validated process for sterilisation of donated urine pools to eliminate 
infectious prions 
5 testing for PrP in urine pools used to manufacture gonadotropins 
6 testing for PrP in the final product 
7 banning the use of urine-derived fertility products 
8 banning the use of recombinant fertility products 
9 screening for the presence of PrPSc in donated urine using a sensitive, validated test 
10 testing for PrPSc using a sensitive, validated test in the final product. 
The effectiveness of the risk management strategies was classified into five categories: 
1 extremely effective 
2 very effective 
3 moderately effective 
4 minimally effective 
5 not at all effective. 
In order to allow individual experts to express some degree of uncertainty as to which 
particular management strategy should be assigned, each expert was told they had a 
mythical €10 to invest on the options, with minimum stake size of €1. The experts 
endowed their stakes – as each judged appropriate – on the five effectiveness categories 
for the ten strategies and the responses of the expert panel were conflated and normalised 
to 100. In this way, indicative weights were ascribed to the alternatives, on the strength of 
the expert judgments. 
3 Results 
3.1 Expert elicitation 
The individual expert responses to the 26 target questions are shown in Figures S1–S26, 
provided in the supplementary material (available at: https://dataverse.harvard.edu/ 
dataset.xhtml?persistentId=doi%3A10.7910%2FDVN%2FREVVTB#). For reach expert, 
the 5th and 95th percentiles denote their reported credible range, with the 50th percentile 
representing their central value judgment in response to these questions (the unweighted 
and weighted combinations of their individual opinions are designated by ‘Equal’ and 
‘Perf’ in the figures). The performance weighted median and 90% credible interval for 
the 26 target questions are summarised in Table 1. 
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Table 1 Median performance-weighted responses and 90% credible intervals provided by the 
experts to target questions 1–26 
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Table 1 Median performance-weighted responses and 90% credible intervals provided by the 
experts to target questions 1–26 (continued) 
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3.2 Prevalence of asymptomatic prion disease in the general population 
Target questions 1–8 asked the experts to estimate the current prevalence of 
asymptomatic vCJD and CJD in the general population from four different regions: the 
UK, European Union excluding the UK, North America and South America. The median 
prevalence estimates for CJD estimates were similar in these four regions, in the range of 
1 in 200,000 to 1 in 400,000. However, prevalence estimates for asymptomatic vCJD 
reflected the known distribution of reported cases, being highest in the United Kingdom 
(median prevalence of asymptomatic vCJD was estimated at 1 in 100,000), followed by a 
smaller number of cases within the European Union (median asymptomatic vCJD 
estimate of 1 in 7 × 106) and even fewer cases reported in North and South America 
(median asymptomatic vCJD estimates of 1 in 4 × 107 and 1 in 5 × 107 respectively). 
Target questions 9–16 asked the experts to estimate the current prevalence of 
asymptomatic vCJD and CJD in post-menopausal women in these four regions The 
median prevalence estimates provided by the experts showed a similar pattern to those 
given for the general population in Table 1. 
3.3 Presence of infectious prions in urine 
Target questions 17 and 18 asked the experts to estimate the likelihood that infectious 
prion protein could be present in the urine of asymptomatic people with vCJD and CJD. 
In both cases, the experts indicated that prion protein could be present in urine of both 
vCJD and CJD patients, given the lengthy asymptomatic phase of these two diseases. 
Median estimates of the likelihood of infectious prions being present in urine were at 
85% for asymptomatic vCJD cases and 15% for asymptomatic CJD cases. 
3.4 Transmission of prion disease through urine-derived fertility drugs 
Target questions 19–22 focused on transmission of prion disease via urine. Considering 
the current selection criteria for urine donors and current manufacturing processes (target 
questions 19 and 20), the expert group estimated the likelihood that infectious prions are 
present in urine-derived fertility drugs to be 1.4% for vCJD and 8% for CJD. These 
values reflect the smaller number of vCJD cases relative to CJD cases that could 
contaminate urine pools and the opinion those prions can co-purify during manufacturing 
of urine-derived fertility drugs. 
Target questions 21 and 22 asked the experts to judge the likelihood that prion disease 
could be contracted through the use of urine-derived fertility drugs, due to the presence of 
infectious prions either from asymptomatic vCJD or CJD cases in human urine pools 
used to manufacture such drugs. In both cases, the risk of contracting prion disease via 
this route of transmission was estimated to be 1% by the experts, with 90% credible 
intervals ranging from 0%–11% in the case of urine samples from asymptomatic vCJD 
urine donors and 0–10% for asymptomatic CJD donors. 
3.5 Relative risk of urine-derived and recombinant fertility drugs 
Target questions 23–26 asked the experts to judge the relative risk of urine-derived and 
recombinant fertility drugs. Target questions 23 and 24 asked the experts to judge the 
likelihood that prion disease could be contracted through the use of fertility drugs 
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manufactured using recombinant methods, either without or with the use of fetal bovine 
serum. The median values of <10–6% (less than one in 100 million) and < 10–7% (less 
than one in a billion) reveal that the experts placed these at a much lower risk for prion 
disease transmission through the use of recombinant fertility drugs than urine-derived 
fertility drugs. 
Table 2 Distribution of expert rating of effectiveness of strategies for managing the risk of 
prion disease from urine-derived fertility drugs 
Strategy Not at all effective 
Minimally 
effective 
Moderately 
effective 
Very 
effective 
Extremely 
effective 
1 Donor 
selection/sourcing 
from countries 
without CJD 
87.5 0.0 12.5 0.0 0.0 
2 Donor 
selection/sourcing 
based on time spent in 
the UK 
12.5 32.5 41.3 13.8 0.0 
3 Donor 
selection/sourcing 
based on blood 
transfusion, 
neurosurgery, or 
exposure to growth 
hormone 
15.0 31.3 26.3 12.5 15.0 
4 Implementing a 
validated process for 
prion sterilisation of 
urine pools 
12.5 12.5 23.8 21.3 30.0 
5 Testing for PrP in 
urine pools used to 
manufacture 
gonadotropins 
75.0 12.5 12.5 0.0 0.0 
6 Testing for PrP in the 
final product 
62.5 0.0 6.3 16.3 15.0 
7 Banning the use of 
urine-derived fertility 
products 
12.5 12.5 0.0 2.5 72.5 
8 Banning the use of 
recombinant fertility 
products 
100.0 0.0 0.0 0.0 0.0 
9 Testing for PrPSc 
using a sensitive, 
validated test in urine 
donor 
0.0 11.7 31.7 45.0 11.7 
10 Testing for PrPSc 
using a sensitive, 
validated test in final 
product 
0.0 5.0 15.0 31.7 48.3 
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Finally, target questions 25 and 26 focused on the expert group’s judgment of the relative 
risk of contracting prion disease from urine-derived fertility drugs, as compared to 
fertility drugs manufactured using recombinant methods either with or without fetal 
bovine serum. The experts judged recombinant fertility drugs produced with bovine 
serum to possess 10-fold lower risk, compared to urine-derived fertility drugs. Fertility 
drugs made without fetal bovine serum were judged to present a risk about 1,200 times 
less compared to urine-derived counterparts. The experts’ responses to these last two 
target questions indicated their collective view that the risk of contracting prion disease 
from fertility drugs derived from human urine was higher than the risk from fertility 
drugs made using recombinant methods either with or without the use of fetal bovine 
serum. Further details on the results for target questions 1–26 are provided in the 
supplementary material (available at: https://dataverse.harvard.edu/dataset.xhtml? 
persistentId=doi%3A10.7910%2FDVN%2FREVVTB#). 
3.6 Strategy ranking 
This simple and easily implemented exercise generated semi-quantitative rankings 
regarding the effectiveness of the potential risk management strategies for prion disease 
contracted from taking urine-derived fertility drugs. The results of the strategy ranking 
exercise, in which seven experts ranked the perceived effectiveness of ten strategies for 
managing the potential risks of prion disease from urine-derived fertility drugs, are listed 
in Table 2. While most strategies showed unimodal shape with respect to the distribution 
of expert opinion (including strategies 2, 3, 4, 5, 8, 9 and 10), three strategies exhibited a 
bimodal distribution (strategies 1, 6 and 7), (the reasons for this bimodal pattern of expert 
opinion are unclear at this stage and warrant further investigation). All experts agreed that 
strategy number 8 – banning the use of recombinant fertility drugs – would be 
ineffective. The experts considered banning the use of urine-derived fertility drugs and 
screening such drugs for the presence of infectious prion protein with a sensitive and 
validated PrPSc test to be the two most effective risk reduction strategies. 
4 Discussions 
In review of target questions 1–16 concerning the prevalence of asymptomatic prion 
disease in the general population, it is important to highlight that, according to the 
judgements of the experts, the prevalence of asymptomatic vCJD in the general 
population in North America is very low. This result concurs with surveillance data from 
the US Centers for Disease Control and Prevention (CDC) and Public Health Agency of 
Canada (PHAC) showing only three potential vCJD cases in the US and one case in 
Canada (a Saskatchewan immigrant from the UK) at the time the elicitation was 
conducted. With regard to the coherence of expert responses to the questions, the 
responses demonstrated that one or more experts had markedly different views from 
those of the rest of the panel. The discrepancies seem to involve a single expert, though 
not always the same expert. As it would seem unlikely that one expert had unique 
information not available to the other experts, these discrepancies would seem to reflect 
differences of expert judgement in the face of scientific uncertainty. 
In the case of target questions 17 and 18, regarding the presence of infectious prions 
in urine and urine pools used in the manufacture of fertility drugs, the aggregated experts’ 
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responses indicate concurrence that there is a potential risk of disease associated with 
prion protein being present in the urine of asymptomatic vCJD and CJD patients. In both 
questions, one expert gave likelihoods that were effectively zero for these possibilities, 
whereas others ascribed real non-zero probabilities. Again, such differences may be 
attributed to differences in expert judgements in the absence of clear evidence on which 
to base more firm conclusions. 
Target questions 19–22 dealt with the transmission of prion disease through the use of 
urine-derived fertility drugs. The pooled judgements indicated that there is potential risk 
that prion disease could be contracted through the use of fertility drugs derived from 
human urine contaminated with infectious prion proteins. The elicitation suggested 1% 
likelihood that prion disease could be contracted by using fertility drugs manufactured 
from human urine containing infectious prions of asymptomatic vCJD cases (questions 
21 and 22). According to verbal risk scales, reviewed by Calman and Royston (1997), a 
median 1% or 1-in-100 value is considered to be ‘high risk’, well above de minimis risk 
levels of 1 in a million used by regulators when assessing acceptable risk (Calman and 
Royston, 1997). The range graph results from these questions (see the supplementary 
material) also showed wide-ranging individual uncertainties. For some of these elicited 
questions, one expert ascribed a much higher likelihood to the possibility of such a 
scenario than the rest of the group, while another expert was inclined to express maximal 
uncertainty through their elicited response. Such responses are not fallacious or irrational, 
but signal the real challenge of trying to pin down meaningful likelihoods when data are 
sparse or non-existent; this situation should be communicated to decision takers. 
The likelihood that prion disease could be contracted through the use of fertility drugs 
manufactured using alternative recombinant methods (target questions 23 and 24) were 
considered to be negligible (at or below de minimis risk levels). However, the views of 
one or two experts again deviated from the rest of the group. The relative risks of 
contracting prion disease from urine-derived fertility drugs, as compared to fertility drugs 
manufactured using recombinant methods with or without fetal bovine serum (target 
questions 25 and 26), produced wide-ranging estimates, hinting at a possible dichotomy 
of views on this topic. Disaggregation and further discussion of the factors involved 
might help elucidate the issues better and identify potential knowledge gaps. This last 
remark underlines a potential valuable benefit of conducting a structured elicitation 
exercise: the expert judgments and the demonstration quantitatively of the existence of 
major uncertainties will provoke new lines of thinking and prompt ideas about research 
topics that could be pursued. 
Rather than a fulsome, evidence-based risk assessment, the expert elicitation 
presented here should be regarded as provisional, subject to modification as new 
evidence becomes available. The elicitation results may also provide a basis for 
identifying that significant knowledge gaps exist and for prioritising issues that might be 
amenable to further targeted research. 
From the present expert elicitation, nearly all target questions have large credible 
intervals associated with them, indicating a high degree of uncertainty in relation to the 
questions posed. This is interpreted not as a failure of the elicitation, but as demonstration 
of the extent of genuine scientific uncertainty that presently exists with respect to the 
many challenging issues relating to prion infection processes and risk factors. However, 
the credible intervals obtained by applying weights from the performance-based analysis 
are generally smaller than those calculated with unweighted pooling. This reflects the fact 
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that experts, whose judgements were better validated statistically on the seed questions, 
generally expressed lower judgement uncertainties on the target items. 
In addition to expressing their judgements about the potential risks of prion disease 
associated with the use of fertility drugs, the experts also provided their views on 
strategies that might be considered to manage potential risks of this type. The least 
effective strategies were strategy 1 (donor selection/sourcing from countries without 
CJD; 87.5% not at all effective) and strategy 8 (banning the use of recombinant fertility 
products; 100% not at all effective). Strategy 1 focuses on restricting urine collection to 
countries without CJD; although this may appear, at first, to be an attractive option, it 
would be difficult to implement in practice as there are few countries without reported 
CJD. The expert group was aware of this fact and ranked this strategy as one of the least 
effective options. 
In contrast, strategy 7 (banning the use of urine-derived fertility products; 72.5% 
extremely effective), followed by strategy 10 (testing the final product with a sensitive 
and validated test for PrPSc; 48.3% extremely effective), were ranked as the two most 
effective strategies for managing prion disease risk. While a ban on urine-derived fertility 
products might be seen as prudent from a precautionary point of view, both the benefits 
and risks of fertility drugs and indeed any therapeutic product need to be carefully 
considered throughout the entire life cycle of that product (Institute of Medicine, 2012). 
5 Conclusions 
The present expert elicitation to explore the areas of uncertainty related to prion 
transmission and urine-derived pharmaceuticals was undertaken at a specific point in 
time (specifically in October, 2011). After the expert elicitation meeting, the Canadian 
Fertility and Andrology Society (CFAS) and the European Society of Human 
Reproduction and Embryology (ESHRE) assessed the data from Van Dorsselaer et al. 
(2011), stating that the concern raised by the authors was not substantiated by clinical 
evidence and a causal relationship between urine-derived fertility drugs and prion disease 
had not been demonstrated. It should be emphasised that Van Dorsselaer et al. (2011) 
detected the normal prion form of the prion protein (PrPC) in urine-derived fertility drugs 
and not infectious prion protein (PrPSc). The fertility societies point to the ‘absence of 
evidence’ of prion disease risk, stating that urine-derive gonadotropins have been used 
for over 50 years without reports of prion disease transmission (CFAS Prion Position 
Statement, 2011; ESHRE, 2012). However, this should be qualified by the fact that only 
some countries have set up national CJD and vCJD surveillance systems post-1994, after 
the detection of the first cases of vCJD in the UK. Thus, formal surveillance for CJD and 
vCJD by all potential routes (including urine-derived transmission) has been in place in 
most countries for only about two decades. The fertility societies found the clinical 
significance of the data from Van Dorsselaer et al. (2011) difficult to assess, but remain 
vigilant in reviewing and evaluating new scientific data. 
For human prion disease there is a difference between the level of risk when 
comparing vCJD to sCJD, as reported in the scientific literature. In sCJD patients, small 
quantities of PrPSc have been identified in peripheral organs. Research published after the 
expert elicitation, conducted by Notari et al. (2012), investigated infectivity of urine from 
patients with sCJDMM1, the most common subtype of sCJD; it was found not to contain 
detectable prion infectivity as determined by bioassay and suggests that no significant 
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prionuria occurs in this common subtype of human prion disease. Based on this study, the 
occurrence of infectious prions in sCJD patients’ urine appears to be remote. It was 
further demonstrated that normal urine contains discrete amounts of the C-terminal 
fragment of PrP, matching the C1 fragment, but not full-length PrP. Although C1 may 
not be a good substrate for PrPSc replication it may act as modulator to slow the 
accumulation of neurotoxic forms of PrP (Dagdanova et al., 2010; Westergard et al., 
2011). 
Rubenstein and Chang (2013) found PrPSc in non-CNS human tissues (spleens, lymph 
nodes and tonsils) from sCJD individuals (Rubenstein and Chang, 2013). Using protein 
misfolding cyclic amplification (PMCA) followed by a sensitive immunoassay (surround 
optical fibre immunoassay, SOFIA), PrPSc was detected in the cerebrospinal fluid (CSF) 
but neither in urine nor blood of sCJD patients. More recently, published findings show 
that the blood (plasma fraction) of sCJD patients does contain infectivity that transmits 
transmissible spongiform encephalopathy (TSE) disease to experimental animals with an 
infectivity level similar to that of vCJD (Douet et al., 2014). It is important for public 
health and other stakeholders to be vigilant as research continues to explore the 
complexity of prion biology uncertainties. 
Some studies have demonstrated that prions can be found in the urine excreted by 
scrapie-inoculated laboratory mice and hamsters. Results from these studies also found 
that the infectious urines are excreted from infected animals during both the 
asymptomatic incubation period before the appearance of any clinical signs (Seeger et al., 
2005) and during the symptomatic phase (Seeger et al., 2005; Kariv-Inbal et al., 2006). 
The titer of infectious prions in the urine of scrapie-infected hamsters is comparable to 
that found in their blood (Gregori et al., 2008). 
Prion proteins were detected in human urine-derived gonadotropins (Kuwabara et al., 
2009), but not in the recombinant human gonadotropins (Van Dorsselaer et al., 2011). 
The transmission of CJD through urine has only been demonstrated in a mouse model by 
intracerebral inoculation (Tateishi, 1985). Again, it must be emphasised that no human 
case of urinary transmission of CJD has been reported to date. 
In vCJD patients, younger individuals are affected (median age at death of 28 years) 
compared to sCJD which affects older individuals (median age at death of 68 years). 
PrPSc is found in the brain and in non-CNS human tissues (spleens, lymph nodes and 
tonsils) of vCJD patients. The peripheral PrPSc levels in sCJD and vCJD individuals were 
found not to differ significantly and as anticipated, were several logs lower than amounts 
found in brain (Rubenstein and Chang, 2013). 
Following the completion of the expert elicitation reported here, Moda et al. (2014) 
reported finding infectious prion proteins in urine samples from vCJD patients. 
Specifically, PrPSc was detected in 13 of 14 urine samples from patients with vCJD, but 
not in urine samples from 68 sCJD patients, 4 patients with genetic CJD patients,  
50 patients with other neurodegenerative disorders, or 50 healthy controls. Although the 
positive samples contained only minute quantities of PrPSc, the detection of infectious 
prions only in urine samples from vCJD patients suggests that urine from vCJD patients 
could be uniquely affected within the CJD family of diseases. 
There are lengthy incubation times for human prion diseases and the existence of 
subclinical infections in M129M, M129V and V129V PRNP carriers that increases the 
uncertainty surrounding the future trajectory of vCJD infections which has implications 
for the management of blood, blood products and handling of surgical instruments (Gill 
et al., 2013; Peden et al., 2004). 
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Sourcing of urine pools is considered to be an important TSE risk reduction factor. A 
2007 European Medicines Agency expert panel reported the TSE risk linked to 
gonadotrophins derived from the urine of post-menopausal Argentine women can be 
considered a negligible risk for a number of reasons including: 
1 Argentina’s negligible BSE risk (GBR I) status 
2 the absence of vCJD cases 
3 the selection of donors with no known TSE risk 
4 the theoretical TSE removal capacity of the manufacturing process. 
Moreover, women treated with fertility drugs are injected by subcutaneous routes of 
administration, which is known to be a relatively inefficient route for transmitting TSEs 
(EMAR, 2009). 
During the present elicitation, the experts indicated that there was a possibility that 
prion disease could be transmitted through the use of fertility medications derived from 
urine contaminated with infectious prions from asymptomatic CJD cases. However, the 
evidence discussed previously suggests a greater concern about urine-derived from vCJD 
rather than sCJD cases. 
Not only is the risk profile associated with the transmission via urine for vCJD 
different to sCJD it highlights that there is also a differing geographic risk profile 
associated with vCJD. 
Due to specified risk material (SRM) bans in many affected countries, new cases of 
vCJD by consuming contaminated meat products have sharply declined (Bradley et al., 
2006). A recent British survey has estimated that approximately 1 in 2,000 people in the 
population may be silent carriers of vCJD based on detecting prion protein in their 
lymphorecticular tissue (Gill et al., 2013). vCJD has been documented to be transmissible 
by blood as there are four known cases in the UK where patients received blood 
transfusion from pre-symptomatic donors and subsequently developed clinical vCJD 
(Llewelyn et al., 2004; Peden et al., 2004), showing that people can contract vCJD and 
incubate as asymptomatic carriers by means other than consuming infected bovine 
products. The risk of asymptomatic carriers was first highlighted when low levels of 
infectivity were detected in blood components of mice infected with a human-derived 
strain of vCJD during both the preclinical and clinical phases of the disease 
(Cervenakova et al., 2003). Thus, for some areas, such as the UK and France, 
transmission of vCJD by silent carriers may present more concern for disease 
transmission through blood or other blood products sourced from humans in those 
countries. 
Although there is no known case for contracting prion diseases through the 
administration of urine-derived human gonadotropins, the widespread use of these drugs 
by over 300,000 women in the US and Canada for infertility treatment makes it a 
potential health risk to the public. Indeed, there were precedents in Australia where four 
known cases of CJD occurred, transmitted by taking fertility drugs derived from human 
pituitary hormone (gonadotropins) (Boyd et al., 2001). In addition, the purification 
procedures used to isolate therapeutic gonadotropins from human urine may also enrich 
the prion proteins, as demonstrated by close to 200 cases of CJD infection through 
intramuscular injections of pituitary growth hormone-derived from human cadavers in the 
1990s (Brown et al., 2006). In some French batches of these pituitary growth hormones, 
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the recipient CJD disease rates were reported to exceed 10%, which highlighted the high 
infectivity of parenterally-injected prions present in some gonadotropin preparations. 
The findings that normal and infectious prion protein can be found in human urine 
(Moda et al., 2014; Van Dorsselaer et al., 2011) may warrant a reassessment of whether 
or not the risks of urine-derived fertility drugs may outweigh their benefits. The judgment 
of whether the outcomes of the present elicitation exercise are helpful in this regard is 
ultimately a matter for regulatory authorities responsible for evaluating public health 
issues relating to fertility drugs and prion diseases to decide. 
While a formal assessment of the likelihood of prion disease transmission through the 
use of urine-derived fertility drugs is impossible due to a current lack of relevant 
scientific data, the structured expert elicitation provided a useful means of addressing 
prion disease risk uncertainties associated with urine-derived fertility drugs, thereby 
serving to characterise the scientific uncertainty surrounding this issue (Institute of 
Medicine, 2014). The use of recombinant gonadotropins was also taken into 
consideration during the expert elicitation process as a viable alternative, which does not 
require extraction from human urine. Although the present expert elicitation judged 
recombinant fertility drugs to carry relatively less risk than urine-derived fertility drugs, 
expert opinions will continue to evolve as new scientific information of the type 
summarised herein becomes available. 
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